4月27日，副省长方伟赴镇江检查安全生产工作。省政府副秘书长徐华勤参加检查。市委常委、常 务副市长张克陪同检查。 在江苏金斯瑞生物科技有限公司，方伟深入企业生产和研发一线，详细了解企业安全管理体系建设 和安全生产责任制落实情况。得知企业建立了EHS基本安全准则，成立了安全生产委员会，配备专职安 全管理机构EHS部门，方伟给予肯定。他指出，生物科技行业技术密集、工艺复杂，安全风险点多、管 理要求高，企业必须树牢底线思维，强化安全管理，持续完善安全生产各项制度，提升本质安全水平， 切实将安全责任落实到每一个岗位、每一名员工。 随后，方伟来到镇江信缘康米山颐养院，实地检查消防控制室、消防设施设备运行状况以及疏散通 道设置情况，仔细询问火灾防控、应急预案制定、日常巡查制度和员工安全培训等工作落实情况。在认 真听取养老机构负责人介绍后，方伟指出，养老机构入住人员多为高龄老人，行动不便、应急反应能力 弱，消防安全责任重大。要深刻吸取近期各地火灾事故教训，进一步压实安全管理责任，全面开展风险 隐患排查整治，完善应急处置预案，加强员工技能培训和演练，做到早发现、早处置，确保遇到突发情 况能够及时组织有效应对，切实守护入住老人 ...

Core Insights - Krystal Biotech, Inc. will present multiple programs related to lung, eye, and skin at scientific conferences in May and June 2025 [1] Conference Presentations - The company will participate in the following conferences: - American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting: Invited Oral Presentation [2] - 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: Poster Presentation [2] - Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting: Poster Presentation [2] - Society for Investigative Dermatology (SID) 2025 Annual Meeting: Poster Presentation [3] Company Overview - Krystal Biotech, Inc. is a global biotechnology company focused on genetic medicines for diseases with high unmet medical needs [4] - The company's first commercial product, VYJUVEK®, is the first-ever redosable gene therapy approved by the FDA for dystrophic epidermolysis bullosa [4] - The company is advancing a pipeline of investigational genetic medicines across various fields including respiratory, oncology, dermatology, ophthalmology, and aesthetics [4]

PITTSBURGH, April 17, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 6, 2025, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Tuesday, May 6, 2025, to discuss the financial results and provide a business update. Investors and the general public can access the live webcas ...

PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an ext ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.Krystal Biotech (NASDAQ: KRYS ) has been on the Compounding Healthcare “Bio Boom” speculative portfolio since the investing group’s inception due to their ability to develop cutting-edge “redosable” gene therapies. Although I am a big believer in cell an ...

Core Insights - Zacks Premium provides tools for investors to enhance their stock market engagement and confidence through daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum characteristics, serving as complementary indicators to the Zacks Rank [2][3] - Each stock receives a rating from A to F, with A indicating the highest potential for outperforming the market [3] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [3][4] Growth Score - The Growth Style Score evaluates stocks based on projected and historical earnings, sales, and cash flow to identify sustainable growth opportunities [4] Momentum Score - The Momentum Style Score assesses stocks based on price trends and earnings estimate changes to identify favorable buying opportunities [5] VGM Score - The VGM Score combines the Value, Growth, and Momentum Scores, providing a comprehensive indicator for stock selection [6] Zacks Rank - The Zacks Rank utilizes earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988 [7][8] - There are over 800 top-rated stocks available, making it essential to use Style Scores for effective selection [9] Stock to Watch: Krystal Biotech, Inc. (KRYS) - Krystal Biotech is a biotechnology company focused on genetic medicines, currently holding a 2 (Buy) Zacks Rank and a VGM Score of B [12] - The company has seen a 17.1% increase in shares over the past four weeks, with upward revisions in earnings estimates for fiscal 2025 [12][13] - The Zacks Consensus Estimate for KRYS has risen by $1.06 to $7.06 per share, with an average earnings surprise of 3.3% [13]

Core Insights - Krystal Biotech (KRYS) shares have increased by 15.8% over the past month, outperforming the industry growth of 4% [1] - The company reported fourth-quarter 2024 results with earnings exceeding estimates, although sales fell short [1] - The stock's surge post-earnings is attributed to strong uptake of Vyjuvek and positive pipeline developments [1] Vyjuvek Performance - Vyjuvek, the first FDA-approved gene therapy for dystrophic epidermolysis bullosa (DEB), was launched in May 2023 [3] - Sales of Vyjuvek reached $290.5 million, a significant increase from $50.7 million in 2023 [4] - As of February 2025, Krystal secured over 510 reimbursement approvals for Vyjuvek in the U.S., with 97% of lives covered under commercial and Medicaid plans [5] Regulatory Approvals - The European Medicines Agency has recommended the approval of Vyjuvek for DEB treatment [6] - A new drug application for Vyjuvek has been filed in Japan, with a decision expected in the second half of 2025 [6] Pipeline Developments - Krystal is advancing a pipeline of genetic medicines across various fields, including respiratory and oncology [7] - KB407 is being evaluated for cystic fibrosis, with interim data expected in mid-2025 [8] - KB408 is showing promising results for alpha-1 antitrypsin deficiency, with further assessments planned [9] Financial Metrics - KRYS shares currently trade at a price/sales ratio of 10.58x forward sales, lower than its historical mean of 22.83x [13] - The Zacks Consensus Estimate for 2025 earnings per share (EPS) has risen to $7.07 from $5.40 over the past month [14] Cash Position - As of December 31, 2024, Krystal holds a cash balance of $749.6 million, positioning the company well for pipeline development [17] Market Position - Krystal Biotech holds a Zacks Rank 2 (Buy), indicating strong market confidence [18]

Core Viewpoint - Krystal Biotech's Vyjuvek has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the treatment of dystrophic epidermolysis bullosa (DEB), with a final decision expected in Q2 2025 [1][3]. Group 1: Product and Approval Details - Vyjuvek is a non-invasive, topical gene therapy designed to deliver two copies of the COL7A1 gene directly to DEB wounds [2]. - The CHMP's favorable opinion supports administration in healthcare settings or at home, with trained patients or caregivers able to apply it themselves [3]. - The positive opinion is based on results from phase I/II GEM-1 and phase III GEM-3 studies, demonstrating successful gene delivery and durable wound closure [5]. Group 2: Market and Financial Performance - Krystal Biotech's shares have declined 18.3% over the past three months, contrasting with a 0.6% decline in the industry [4]. - In Q4 2024, the company reported total revenues of $91.1 million, a 116% increase year-over-year, solely from Vyjuvek sales [8]. - As of February 2025, the company secured over 510 reimbursement approvals for Vyjuvek in the U.S., with a gross margin of 95% in Q4 2024 and high patient adherence at 85% [9]. Group 3: Future Launch Plans - Krystal Biotech plans to launch Vyjuvek for DEB in Germany around mid-2025, with additional launches in France and other EU countries later in 2025 [7].

Core Viewpoint - The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive recommendation for the approval of VYJUVEK for treating wounds in patients with dystrophic epidermolysis bullosa, with a final decision expected in the second quarter of 2025 [1][2]. Group 1: Product Information - VYJUVEK is a non-invasive, topical gene therapy designed to deliver two copies of the COL7A1 gene directly to DEB wounds, addressing the fundamental disease-causing mechanism [6]. - The therapy promotes durable wound closure and is suitable for patients from birth, with administration options available for trained patients or caregivers at home [1][4]. - VYJUVEK was previously approved in the United States in May 2023 for patients six months of age and older [6][9]. Group 2: Clinical Evidence - The CHMP's positive opinion is based on comprehensive clinical data from the Phase 1/2 GEM-1 and Phase 3 GEM-3 studies, which demonstrated successful COL7A1 gene delivery and durable wound closure [3]. - Long-term safety and efficacy are supported by results from an open-label extension study in the U.S. and real-world experience since the product's U.S. launch [3]. Group 3: Market Strategy - The company plans to launch VYJUVEK in Germany around mid-2025, followed by a launch in France later that year, aiming to maximize patient access [5]. - The approval by the EC would allow the company to market B-VEC under the registered European trademark VYJUVEK across the EU and additional countries [4].

Company Overview - Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines to address diseases with high unmet medical needs [3] - The company's first commercial product, VYJUVEK®, is the first-ever redosable gene therapy and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa [3] - Krystal Biotech is advancing a robust pipeline of investigational genetic medicines across various fields including respiratory, oncology, dermatology, ophthalmology, and aesthetics [3] Upcoming Events - The company will participate in the TD Cowen 45th Annual Health Care Conference on March 4, 2025, in Boston [1] - Krish S. Krishnan, the Chairman and CEO, will engage in a fireside chat at 1:50 pm ET and will host investor meetings throughout the day [1] - A webcast of the presentation will be available starting at 1:50 pm ET on March 4, 2025, and will be posted on the company's website [2]